Immunome (NASDAQ:IMNM) Sets New 12-Month High – What’s Next?

Immunome, Inc. (NASDAQ:IMNM) reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $20.65 and last traded at $20.54, with a volume of 118976 shares traded. The stock had previously closed at $20.30.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IMNM. Wall Street Zen upgraded shares of Immunome from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. The Goldman Sachs Group initiated coverage on Immunome in a research note on Monday, September 22nd. They issued a “buy” rating and a $26.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a research report on Wednesday, October 8th. Guggenheim reaffirmed a “buy” rating and set a $25.00 price target on shares of Immunome in a research report on Monday, August 25th. Finally, Craig Hallum began coverage on Immunome in a research note on Friday, September 5th. They set a “buy” rating and a $26.00 price target for the company. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Immunome Stock Performance

The firm has a market cap of $1.83 billion, a P/E ratio of -6.78 and a beta of 2.17. The firm has a 50 day simple moving average of $16.64 and a 200 day simple moving average of $12.12.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Sell-side analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently modified their holdings of IMNM. MetLife Investment Management LLC grew its holdings in shares of Immunome by 19.1% during the first quarter. MetLife Investment Management LLC now owns 42,411 shares of the company’s stock worth $285,000 after purchasing an additional 6,792 shares in the last quarter. Tema Etfs LLC bought a new stake in Immunome during the second quarter valued at approximately $1,074,000. Kennedy Capital Management LLC grew its stake in Immunome by 642.6% in the 2nd quarter. Kennedy Capital Management LLC now owns 109,352 shares of the company’s stock worth $1,017,000 after buying an additional 94,627 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Immunome by 55.0% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 775,000 shares of the company’s stock worth $5,216,000 after buying an additional 275,000 shares during the last quarter. Finally, Exome Asset Management LLC purchased a new stake in shares of Immunome during the 1st quarter valued at $1,776,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.